Skip to main content
PMC home page
The Indian Journal of Surgery logoLink to The Indian Journal of Surgery
. 2010 Jan 13;71(6):342–349. doi: 10.1007/s12262-009-0092-6

Advances in the management of gastric cancer

Manas Kumar Roy 1,✉, Sagar Sadhu 1, Sanjay Kumar Dubey 1
PMCID: PMC3452751  PMID: 23133189

Abstract

Gastric cancer is a common malignancy in our country and patients continue to present at an advanced stage. Following confirmation of diagnosis, CT scan, endoscopic ultrasound and laparoscopy are the essential staging modalities. Radical gastrectomy remains the initial treatment of choice. Although controversy persists about the extent of lymph node dissection, there is a general consensus in performing D2 dissection but with preservation of pancreas and spleen. Patients who have high risk of relapse are treated with postoperative chemoradiotherapy. The regimen of preoperative chemotherapy followed by gastrectomy and postoperative chemotherapy has also become important in recent years. Both these chemotherapeutic options confer survival advantage and patients need to be appraised about various treatment strategies at the very outset.

Keywords: Gastric cancer, Surgery, Adjuvant therapy

Full Text

The Full Text of this article is available as a PDF (260.4 KB).

References

  • 1.National Cancer Registry Programme (ICMR). Population based cancer registry 2004–2005. http://www.pbcrindia.org
  • 2.Yeole B.B. Trends in cancer incidence in esophagus, stomach, colon, rectum and liver in males in India. Asian Pac J Cancer Prev. 2008;9(1):97–100. [PubMed] [Google Scholar]
  • 3.Shrikhande S.V., Shukla P.J., Qureshi S., Siddachari R., Upasani V., Ramadwar M., Kakade A.C., Hawaldar R. D2 lymphadenectomy for gastric cancer in Tata Memorial Hospital: Indian data can now be incorporated in future international trials. Dig Surg. 2006;23(3):192–197. doi: 10.1159/000094537. [DOI] [PubMed] [Google Scholar]
  • 4.National Comprehensive Cancer Network Clinical Pratice Guidelines in Oncology. Gastric Cancer V.2.2009. http://www.nccn.org
  • 5.Jadvar H., Tatlidil R., Garcia A.A., Conti P.S. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol. 2003;58(3):215–221. doi: 10.1016/S0009-9260(02)00477-4. [DOI] [PubMed] [Google Scholar]
  • 6.Tsendsuren T., Jun S.M., Mian X.H. Usefulness of endoscopic ultrasonography in preoperative TNM staging of gastric cancer. World J Gastroenterol. 2006;12(1):43–47. doi: 10.3748/wjg.v12.i1.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sarela A.I., Lefkowitz R., Brennan M.F., Karpeh M.S. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191(1):134–138. doi: 10.1016/j.amjsurg.2005.10.015. [DOI] [PubMed] [Google Scholar]
  • 8.Bentrem D., Wilton A., Mazumdar M., Brennan M., Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12(5):347–353. doi: 10.1245/ASO.2005.03.065. [DOI] [PubMed] [Google Scholar]
  • 9.Bentrem D., Gerdes H., Tang L., Brennan M., Coit D. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol. 2007;14(6):1853–1859. doi: 10.1245/s10434-006-9037-5. [DOI] [PubMed] [Google Scholar]
  • 10.Sarela A.I., Miner T.J., Karpeh M.S., Coit D.G., Jaques D.P., Brennan M.F. Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg. 2006;243(2):189–195. doi: 10.1097/01.sla.0000197382.43208.a5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Maruyama K., Okabayashi K., Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg. 1987;11(4):418–425. doi: 10.1007/BF01655804. [DOI] [PubMed] [Google Scholar]
  • 12.Bunt A.M., Hermans J., Smit V.T., Velde C.J., Fleuren G.J., Bruijn J.A. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol. 1995;13(1):19–25. doi: 10.1200/JCO.1995.13.1.19. [DOI] [PubMed] [Google Scholar]
  • 13.Sasako M., McCulloch P., Kinoshita T., Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82(3):346–351. doi: 10.1002/bjs.1800820321. [DOI] [PubMed] [Google Scholar]
  • 14.Sue-Ling H. Radical D2 gastrectomy for cancer. The case of D2 resections. Ann R Coll Surg Engl. 2007;89(7):672–674. doi: 10.1308/003588407X209518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Gall F.P., Hermanek P. New aspects in the surgical treatment of gastric carcinoma — a comparative study of 1636 patients operated on between 1969 and 1982. Eur J Surg Oncol. 1985;11:219–225. [PubMed] [Google Scholar]
  • 16.Shiu M.H., Moore E., Sanders M., Huvos A., Freedman B., Goodbold J., Chaiyaphruk S., Wesdorp R., Brennan M.F. Influence of the extent of resection on survival after curative treatment of gastric carcinoma. A retrospective multivariate analysis. Arch Surg. 1987;122:1347–1351. doi: 10.1001/archsurg.1987.01400230135024. [DOI] [PubMed] [Google Scholar]
  • 17.Gunderson L.L., Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8(1):1–11. doi: 10.1016/0360-3016(82)90377-7. [DOI] [PubMed] [Google Scholar]
  • 18.Ochiai T., Sasako M., Mizuno S., Kinoshita T., Takayama T., Kosuge T., Yamazaki S., Maruyama K. Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br J Surg. 1994;81(8):1175–1178. doi: 10.1002/bjs.1800810832. [DOI] [PubMed] [Google Scholar]
  • 19.Cuschieri A., Fayers P., Fielding J., Craven J., Bancewicz J., Joypaul V., Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–999. doi: 10.1016/S0140-6736(96)90144-0. [DOI] [PubMed] [Google Scholar]
  • 20.Cuschieri A., Weeden S., Fielding J., Bancewicz J., Craven J., Joypaul V., Sydes M., Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79(9–10):1522–1530. doi: 10.1038/sj.bjc.6690243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Bonenkamp J.J., Songun I., Hermans J., Sasako M., Welvaart K., Plukker J.T., Elk P., Obertop H., Gouma D.J., Taat C.W., et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–748. doi: 10.1016/S0140-6736(95)90637-1. [DOI] [PubMed] [Google Scholar]
  • 22.Bonenkamp J.J., Hermans J., Sasako M., Velde C.J., Welvaart K., Songun I., Meyer S., Plukker J.T., Elk P., Obertop H., Gouma D.J., Lanschot J.J., Taat C.W., Graaf P.W., Meyenfeldt M.F., Tilanus H. Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–914. doi: 10.1056/NEJM199903253401202. [DOI] [PubMed] [Google Scholar]
  • 23.Hartgrink H.H., Velde C.J., Putter H., Bonenkamp J.J., Klein Kranenbarg E., Songun I., Welvaart K., Krieken J.H., Meijer S., Plukker J.T., Elk P.J., Obertop H., Gouma D.J., Lanschot J.J., Taat C.W., Graaf P.W., Meyenfeldt M.F., Tilanus H., Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069–2077. doi: 10.1200/JCO.2004.08.026. [DOI] [PubMed] [Google Scholar]
  • 24.Sue-Ling H.M., Johnston D. D1 versus D2 dissection for gastric cancer. Lancet. 1995;345(8963):1515–1516. doi: 10.1016/S0140-6736(95)91078-6. [DOI] [PubMed] [Google Scholar]
  • 25.Parikh D., Johnson M., Chagla L., Lowe D., McCulloch P. D2 gastrectomy: lessons from a prospective audit of the learning curve. Br J Surg. 1996;83(11):1595–1599. doi: 10.1002/bjs.1800831134. [DOI] [PubMed] [Google Scholar]
  • 26.Brennan M.F. Lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):956–958. doi: 10.1056/NEJM199903253401210. [DOI] [PubMed] [Google Scholar]
  • 27.Sasako M. Recent Advances in Surgery. 23rd edition. Delhi: Harcourt Publishers Ltd.; 2000. Surgery for gastric cancer; pp. 11–21. [Google Scholar]
  • 28.Sano T., Katai H., Sasako M., Maruyama K. One thousand consecutive gastrectomies without operative mortality. Br J Surg. 2002;89(1):123. [PubMed] [Google Scholar]
  • 29.Mullen J.T., Pisters P.W.T. Mastery of Surgery. 5th edition. Philadelphia: Lippincott Williams & Wilkins; 2007. Subtotal gastrectomy for gastric cancer; pp. 927–937. [Google Scholar]
  • 30.Otsuji E., Yamaguchi T., Sawai K., Okamoto K., Takahashi T. End results of simultaneous pancreatectomy, splenectomy and total gastrectomy for patients with gastric carcinoma. Br J Cancer. 1997;75(8):1219–1223. doi: 10.1038/bjc.1997.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Griffith J.P., Sue-Ling H.M., Martin I., Dixon M.F., McMahon M.J., Axon A.T., Johnston D. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut. 1995;36(5):684–690. doi: 10.1136/gut.36.5.684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Csendes A., Burdiles P., Rojas J., Braghetto I., Diaz J.C., Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery. 2002;131(4):401–407. doi: 10.1067/msy.2002.121891. [DOI] [PubMed] [Google Scholar]
  • 33.Weitz J., Jaques D.P., Brennan M., Karpeh M. Association of splenectomy with postoperative complications in patients with proximal gastric and gastroesophageal junction cancer. Ann Surg Oncol. 2004;11(7):682–689. doi: 10.1245/ASO.2004.03.048. [DOI] [PubMed] [Google Scholar]
  • 34.McCulloch P., Nita M.E., Kazi H., Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev. 2004;18(4):CD001964. doi: 10.1002/14651858.CD001964.pub2. [DOI] [PubMed] [Google Scholar]
  • 35.Degiuli M., Sasako M., Calgaro M., Garino M., Rebecchi F., Mineccia M., Scaglione D., Andreone D., Ponti A., Calvo F., Italian Gastric Cancer Study Group Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol. 2004;30(3):303–308. doi: 10.1016/j.ejso.2003.11.020. [DOI] [PubMed] [Google Scholar]
  • 36.Siewert J.R., Böttcher K., Roder J.D., Busch R., Hermanek P., Meyer H.J. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993;80(8):1015–1018. doi: 10.1002/bjs.1800800829. [DOI] [PubMed] [Google Scholar]
  • 37.Wu C.W., Hsiung C.A., Lo S.S., Hsieh M.C., Chen J.H., Li A.F., Lui W.Y., Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7(4):309–315. doi: 10.1016/S1470-2045(06)70623-4. [DOI] [PubMed] [Google Scholar]
  • 38.Karpeh M.S., Leon L., Klimstra D., Brennan M.F. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg. 2000;232(3):362–371. doi: 10.1097/00000658-200009000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Coburn N.G. Lymph nodes and gastric cancer. J Surg Oncol. 2009;99(4):199–206. doi: 10.1002/jso.21224. [DOI] [PubMed] [Google Scholar]
  • 40.Joyce D.J., McCulloch P. Textbook of Surgical Oncology. London: Informa; 2007. Gastric cancer; pp. 172–181. [Google Scholar]
  • 41.Davies J., Johnston D., Sue-Ling H., Young S., May J., Griffith J., Miller G., Martin I. Total or subtotal gastrectomy for gastric carcinoma? A study of quality of life. World J Surg. 1998;22(10):1048–1055. doi: 10.1007/s002689900515. [DOI] [PubMed] [Google Scholar]
  • 42.Harrison L.E., Karpeh M.S., Brennan M.F. Total gastrectomy is not necessary for proximal gastric cancer. Surgery. 1998;123(2):127–130. [PubMed] [Google Scholar]
  • 43.Kim S.H., Karpeh M.S., Klimstra D.S., Leung D., Brennan M.F. Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg. 1999;3(1):24–33. doi: 10.1016/S1091-255X(99)80004-3. [DOI] [PubMed] [Google Scholar]
  • 44.Reyes C.D., Weber K.J., Gagner M., Divino C.M. Laparoscopic vs open gastrectomy. A retrospective review. Surg Endosc. 2001;15(9):928–931. doi: 10.1007/s004640080185. [DOI] [PubMed] [Google Scholar]
  • 45.Huscher C.G., Mingoli A., Sgarzini G., Sansonetti A., Paola M., Recher A., Ponzano C. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg. 2005;241(2):232–237. doi: 10.1097/01.sla.0000151892.35922.f2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Strong V.E., Devaud N., Allen P.J., Gonen M., Brennan M.F., Coit D. Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. Ann Surg Oncol. 2009;16(6):1507–1513. doi: 10.1245/s10434-009-0386-8. [DOI] [PubMed] [Google Scholar]
  • 47.Hoya Y., Mitsumori N., Yanaga K. The advantages and disadvantages of a Roux-en-Y reconstruction after a distal gastrectomy for gastric cancer. Surg Today. 2009;39(8):647–651. doi: 10.1007/s00595-009-3964-2. [DOI] [PubMed] [Google Scholar]
  • 48.Mari E., Floriani I., Tinazzi A., Buda A., Belfiglio M., Valentini M., Cascinu S., Barni S., Labianca R., Torri V. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente) Ann Oncol. 2000;11(7):837–843. doi: 10.1023/A:1008377101672. [DOI] [PubMed] [Google Scholar]
  • 49.Wagner A.D., Grothe W., Behl S., Kleber G., Grothey A., Haerting J., Fleig W.E. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2005;2:CD004064. doi: 10.1002/14651858.CD004064.pub2. [DOI] [PubMed] [Google Scholar]
  • 50.Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T., Fujii M., Nashimoto A., Furukawa H., Nakajima T., Ohashi Y., Imamura H., Higashino M., Yamamura Y., Kurita A., Arai K., ACTS-GC Group Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–1820. doi: 10.1056/NEJMoa072252. [DOI] [PubMed] [Google Scholar]
  • 51.Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., Smith D.B., Langley R.E., Verma M., Weeden S., Chua Y.J., MAGIC Trial Participants Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi: 10.1056/NEJMoa055531. [DOI] [PubMed] [Google Scholar]
  • 52.Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., Haller D.G., Ajani J.A., Gunderson L.L., Jessup J.M., Martenson J.A. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–730. doi: 10.1056/NEJMoa010187. [DOI] [PubMed] [Google Scholar]
  • 53.Mansour J.C., Tang L., Shah M., Bentrem D., Klimstra D.S., Gonen M., Kelsen D.P., Brennan M.F., Coit D.G. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14(12):3412–3418. doi: 10.1245/s10434-007-9574-6. [DOI] [PubMed] [Google Scholar]
  • 54.Ott K., Weber W.A., Lordick F., Becker K., Busch R., Herrmann K., Wieder H., Fink U., Schwaiger M., Siewert J.R. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24(29):4692–4698. doi: 10.1200/JCO.2006.06.7801. [DOI] [PubMed] [Google Scholar]
  • 55.House M.G., Brennan M.F. Neoadjuvant therapy for gastric cancer. Advan Surg. 2008;42:151–168. doi: 10.1016/j.yasu.2008.04.003. [DOI] [PubMed] [Google Scholar]
  • 56.Catalano V., Graziano F., Santini D., D’Emidio S., Baldelli A.M., Rossi D., Vincenzi B., Giordani P., Alessandroni P., Testa E., Tonini G., Catalano G. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer. 2008;99(9):1402–1407. doi: 10.1038/sj.bjc.6604732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Yamamoto S. Stomach cancer incidence in the world. Jpn J Clin Oncol. 2001;31:471–477. doi: 10.1093/jjco/31.9.471. [DOI] [PubMed] [Google Scholar]
  • 58.Huang J.Q., Zheng G.F., Sumanac K., Irvine E.J., Hunt R.H. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003;125(6):1636–1644. doi: 10.1053/j.gastro.2003.08.033. [DOI] [PubMed] [Google Scholar]
  • 59.Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R.J. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–789. doi: 10.1056/NEJMoa001999. [DOI] [PubMed] [Google Scholar]
  • 60.Wong B.C., Lam S.K., Wong W.M., Chen J.S., Zheng T.T., Feng R.E., Lai K.C., Hu W.H., Yuen S.T., Leung S.Y., Fong D.Y., Ho J., Ching C.K., Chen J.S. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187–194. doi: 10.1001/jama.291.2.187. [DOI] [PubMed] [Google Scholar]
  • 61.Giudice G., Malfertheiner P., Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev Vaccines. 2009;8(8):1037–1049. doi: 10.1586/erv.09.62. [DOI] [PubMed] [Google Scholar]
  • 62.Bielanski W. Epidemiological study on Helicobacter pylori infection and extragastroduodenal disorders in Polish population. J Physiol Pharmacol. 1999;50:723–733. [PubMed] [Google Scholar]

Articles from The Indian Journal of Surgery are provided here courtesy of Springer

RESOURCES